Nathaniel Odor, MD
Orthopaedic Surgery · Oklahoma City, OKNPI 1588010656
Payments from drug & device makers
What this record shows
This record is dominated by education: $24,455 of the $30,481 with a category attached, or 80.2%. Smith+Nephew accounts for 67.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $12,199 and has fallen 94.3% since, to $695 in 2025.
Across 95 payments — averaging $320.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$21K
- Stryker$5K
- Pylant Medical$4K
- Encore Medical, LP$134
- Zimmer Biomet$126
- Ortho Development Corporation$115
- plus $398 from 11 others
What the payments were for
- Travel & lodging$1,4515%
- Food & beverage$4,57515%
- Education$24,45580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 8 | $20,535 |
| Stryker | 68 | $4,717 |
| Pylant Medical | 3 | $4,455 |
| Encore Medical, LP | 1 | $134 |
| Zimmer Biomet | 1 | $126 |
| Ortho Development Corporation | 1 | $115 |
| Innovation Technologies Inc | 1 | $112 |
| Dynasplint Systems Inc. | 1 | $64 |
| Pacira Pharmaceuticals Incorporated | 3 | $60 |
| Acera Surgical, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| AstraZeneca | 1 | $20 |
| Amgen | 1 | $19 |
| ERMI LLC | 1 | $19 |
| Deroyal Industries, Inc. | 1 | $15 |
| Bioventus LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$2,344
- PROCISE Tonsil$456
- DJO SURGICAL$269
- ROSA-Knee$126
- Balance Knee Revision System$115
- BKS TriMax$115
- Irrisept$112
- ACCOLADE$100
How this compares
$30,481 in reported general payments places this provider in the 85th percentile of 263 orthopaedic surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $19,248 |
| Celecoxib | 88 | $2,149 |
| Oxycodone Hcl | 247 | $1,965 |
| Methocarbamol | 101 | $1,478 |
| Meloxicam | 220 | $1,331 |
| Doxycycline Hyclate | 90 | $1,284 |
| Mupirocin | 160 | $1,264 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $737 |
| Cefadroxil | 48 | $516 |
| Doxycycline Monohydrate | 24 | $457 |
| Gabapentin | 14 | $268 |
| Ondansetron OdtOndansetron | 19 | $253 |
| Hydroxyzine Pamoate | 18 | $142 |
| Tramadol Hcl | 13 | $86 |
| Amoxicillin | 41 | $72 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Oklahoma City
- Andrew ParkinsonOklahoma City$3.1M
- Bradley ReddickOklahoma City$573K
- Jason EmersonOklahoma City$189K
- Ronald DumiganOklahoma City$169K
- Paul MaitinoOklahoma City$110K
- Thomas TkachOklahoma City$83K
- Brian LevingsOklahoma City$80K
- Christopher WhiteOklahoma City$73K
- Raymond SteinmetzOklahoma City$64K
- Michael JohnsonOklahoma City$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.